REGISTERED CHARITY NUMBER: 292909
Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 31 December 2021
for
CANCER TREATMENT AND RESEARCH TRUST
Sandison Lang Limited
2 St Marys Road
Tonbridge
Kent
TN9 2LB
CANCER TREATMENT AND RESEARCH TRUST
Contents of the Financial Statements
for the Year Ended 31 December 2021
|
Page |
Report of the Trustees |
1 to 11 |
Independent Examiner's Report |
12 |
Statement of Financial Activities |
13 |
Balance Sheet |
14 |
Notes to the Financial Statements |
15 to 22 |
Detailed Statement of Financial Activities |
23 to 24 |
CANCER TREATMENT AND RESEARCH TRUST
Report of the Trustees
for the Year Ended 31 December 2021
Thetrusteespresenttheirreportwiththefinancialstatementsofthecharityfortheyear ended
31December2021.ThetrusteeshaveadoptedtheprovisionsofAccountingandReportingby Charities:
StatementofRecommendedPracticeapplicabletocharitiespreparingtheiraccountsinaccordance with
the FinancialReportingStandardapplicablein the UK and Republicof Ireland(FRS 102)(effective1 January
2019).
OBJECTIVES AND ACTIVITIES
Objectives and aims
The CancerTreatmentand ResearchTrust(CTRT)whichwas foundedin 1985,supportsworkmainlyin the
departmentsof medicaloncologyat the West LondonCancerCentre based at Charing Cross Hospitaland in
thedepartmentofmedicaloncologyattheMountVernonCancerCentre,inNorthwood,Middlesex. The
CTRTexiststosupporttreatmentandresearchintomanyformsofmalignantdiseaseandhas been
particularlyinvolvedinunderstandinghowcertaincancersdevelop,findingbetterwaystomonitor them
anddevelopingnewanti-canceragents.Itremainscommittedtofundingresearchthatisnot adequately
funded either by the major cancer charities such as CRUK, the MRC or the pharmaceutical industry.
ACHIEVEMENT AND PERFORMANCE
Charitable activities
The trustees are pleased with the achievements and performance of the Trust in 2021.
In 2021 CTRT contributed to funding for:
Mount Vernon Cancer Centre:
-
Clinical research fellow undertaking a PhD at Brunel University
-
Laboratory technician at Brunel University working on liquid biomarkers
-
Bench fees for a further PhD student at Brunel University
-
Part-time administrator for Rare Neoplasms of Gynaecological Origin, UK-wide tissue and data bank of
-
patients with specified rare gynae cancers
Charing Cross and Hammersmith Hospitals
The research supported by the CTRT can be roughly split into the following areas:
-
Ovarian, uterine and rare gynaecological cancers
-
Lung Cancer
-
Testicular and Ovarian Germ Cell Cancer (GCT)
-
Gestational Trophoblastic Disease
-
Melanoma
-
Renal Cancer
-
Targeting tumour blood vessels
Detailsaboutthe research,togetherwith the relevantpublicationsand studies,are availableon the Trust's
website - cancertreatment.org.uk
Page 1
CANCER TREATMENT AND RESEARCH TRUST
Report of the Trustees
for the Year Ended 31 December 2021
FINANCIAL REVIEW
Financial position
Thefinancialresultsfortheyearareasshowninthefinancialsectionofthisreportandcover accounting
periodof12monthsfrom01January2021to31stDecember2021.Thecarryforwardfundsasat 31st
December2021amountedto£1,049.442,ofwhich£349,411wasrestrictedand£700,031 was
unrestricted.
Wecontinuetooperateinanuncertainenvironmentaffectedbytherestrictionsimposedinresponse to
COVID-19. We monitor, evaluate and adapt fundraising activities to respond to changing regulations.
Reserves policy
Sufficientreservesare maintainedto ensurethat all expenses,as well as futureresearchcosts,are covered
in the event no donations are received in any one year.
For many years the CTRT receivedfunds to pay for researchstaff running clinicaltrials from pharmaceutical
companiesand trialorganisations.IncreasinglythesefundshavebeenpaiddirectlytothelocalNHS Trusts
whoemploythesestaff.As of 1stJanuary2008the accountsrelatedto MountVernonCancerCentre only
include income and expenses actually paid into or out of CTRT accounts.
FUTURE PLANS
- New charity structure
In 2020,theBoardofTrusteesforCTRTwereadvisedtoimplementa newstructureforthecharityin line
withthe CharityCommission'srecommendations.The CTRThas lodgedan applicationforregistrationas a
Charitable Incorporated Organisation (CIO) using one of the models recommended.
- Investing in fundraising
The CTRT updatedand approveda coupleof essentialpolicies.A smallgroup of CTRT volunteershave been
identified.Theyarebeingveryhelpfulinthedevelopmentofasocialmediapresence.Itisenvisaged that
wewillcontinuetoexpandthisgroupandexploreexpandingcurrentandimplementingnew fundraising
initiatives in the next year.
- Plans for research
TheCTRTwillcontinuetosupportadiversevarietyofresearchintoseveraldifferenttypesof common
cancerssuchaslung,ovarianandmelanomaandalsorarecancerssuchasgestational trophoblastic
neoplasiaandovariangermcelltumours.Thisresearchincludesstudiesbothintheclinicandin the
laboratoryfocusedondevelopingnovelbiomarkersandcancertreatmentsemployingthe latest
technologies.Immunotherapycontinuestobeamajorareaofinterestinthecancerworldand CTRT
continuestosupportleadingresearchstudyingtheeffectsofimmunotherapyintrophoblastic,lung and
renal cancers.
Details of previous research and further details about existing projects can be found on the website.
Page 2
CANCER TREATMENT AND RESEARCH TRUST
Report of the Trustees
for the Year Ended 31 December 2021
STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
Thecharityiscontrolledbyitsgoverningdocument,adeedoftrustandconstitutesan unincorporated
charity.
The CancerTreatmentand ResearchTrust(CTRT)whichwas foundedin 1985,supportsworkmainlyin the
departmentsof medicaloncologyat the West LondonCancerCentre based at Charing Cross Hospitaland in
thedepartmentofmedicaloncologyattheMountVernonCancerCentre,inNorthwood,Middlesex. The
CTRTexiststosupporttreatmentandresearchintomanyformsofmalignantdiseaseandhas been
particularlyinvolvedinunderstandinghowcertaincancersdevelop,findingbetterwaystomonitor them
anddevelopingnewanti-canceragents.Itremainscommittedtofundingresearchthatisnot adequately
funded either by the major cancer charities such as CRUK, the MRC or the pharmaceutical industry.
Recruitment and appointment of new trustees
TheCTRTBoardofTrusteesis madeup of9 professionalswithlegalormedicalbackgroundsas regulated
bythedeedoftrustinlinewiththeCharityCommissionregulations.Cancerphysiciansdominate,in line
withtheaimsofthecharity.Thereareplanstoactivelyseeknewtrusteesofnon-medical/ legal
backgrounds.ProfessorMarciaHall,aTrusteewithCTRTforover10years,tookontheroleofChair in
2019/20.
Organisational structure
InMay2021CTRTwasgrantedaCharitableIncorporatedOrganisation(CIO)status,withthe official
transitiondate1stofJanuary2022.Inpreparationforthis,thecharityopenedanewbankaccount and
ensuredtheTransferofAssetswascompletedinlinewiththeCharityCommissionregulations.The old
charity remains open for now.
The Trust'sAdministratorwassupportedby the Boardto ensurethe transferof othercharity's operations,
such as policies, donations and other commitments related to the charitable work of the organisation.
In 2021we mergedMountVernonand CharingCross/Hammersmithwebsitestogether.Information about
CTRT and how to support its work in different areas are available on the cancertreatment.org.uk website.
Page 3
CANCER TREATMENT AND RESEARCH TRUST
Report of the Trustees
for the Year Ended 31 December 2021
STRUCTURE, GOVERNANCE AND MANAGEMENT
Risk management
TheTrusteesareawareoftherisksaffectingtheTrustanditsworkandhaveensuredthatpoliciesare in
place to mitigate the effect of these risks.
- Financial risks and Investment
AkeyaimoftheBoardistoensureCTRTholdsadequatereservesforworkingcapitalpurposesand has
sufficientfundstomeetcontractualliabilitiesandwindingdowncosts,iftheorganisationwereto close.
This includesredundancypay, amountsdue to creditorsand commitmentsunder contracts.CTRT'slevel of
reservesalsohelpstheorganisationtoplanexpenditureagainstvariationsinthewayfundingis received.
Tobalancetheuncertaintyof funding,ourpolicyis tomaintainfinancialreservestocoverthesecosts and
allowforanorderlywinddown.Thecurrentestimateofthesecostsisc£20,000-£30,000. Without
currentlevelofsupportfromourindividualdonorsandbasedoncurrentexpenditurelevels,CTRT is
estimatedtostillremaininapositiontocoverthesecostsforthecomingxxxmonthsasour unrestricted
reserves stand at about £xxx
- Governance structure
Thereviewofgovernancestructure,policiesandprocedureswascommencedandfollowingthat review,
any recommendations made and agreed upon by the trustees will be implemented in the authorised order.
Page 4
CANCER TREATMENT AND RESEARCH TRUST
Report of the Trustees
for the Year Ended 31 December 2021
STRUCTURE, GOVERNANCE AND MANAGEMENT
CONCLUSION
Research, either totally or partly funded by the CTRT led to 40 publications in 2021.
1. SaraviS, Alizzi Z, Tosi S, Hall M, KarterisE.Preclinicalstudies on the effect of rucaparibin ovarian cancer:
impact of BRCA2 status. Cells 2021, 10, 2434 doi.org/10.3390/cells10092434
2.KatopodisP,AnikinV, KishoreU,CarterT,HallM,AsadiN, PolychronisA, KarterisE. Circulating tumour
cellsandcirculatingcell-freeDNAinpatientswithlungcancer:acomparisonbetweenthoracotomy and
video-assistedthorascopicsurgery.BMJOpenRespirRes.2021Sep;8(1):e000917. doi:
10.3390/cells10092434.PMID: 34493540
3.KerslakeR,HallM,VagnarelliP,JeyaneethiJ,RandevaHS,PadosG,KyrouI,KarterisE.A pancancer
overviewofFBN1,asprosinanditscognatereceptorOR4M1withdetailedexpressionprofilingin ovarian
cancer. Oncol Lett. 2021 Sep;22(3):650. doi: 10.3892/ol.2021.12911. Epub 2021 Jul 9.PMID: 34386072
4. BanerjeeSN, Tang M, O'ConnellRL, SjoquistK, Clamp AR, Millan D, NottleyS, Lord R, MullasseryVM, Hall
M, GourleyC, BonaventuraT, GohJC, SykesP, GrantPT,McNallyO, AlexanderL, KellyC, CartyK, Divers L,
BradshawN,EdmondsonRJ,FriedlanderM;PARAGONinvestigators.Aphase2studyofanastrozole in
patientswithoestrogenreceptorand/progesteronereceptorpositiverecurrent/metastaticgranulosa cell
tumours/sex-cordstromaltumoursof theovary:ThePARAGON/ANZGOG0903trial.GynecolOncol. 2021
Aug 16:S0090-8258(21)00586-2. doi: 10.1016/j.ygyno.2021.07.024. Online ahead of print.PMID: 34412908
5.ZahraA,DongQ,HallM,JeyaneethiJ,SilvaE,KarterisE,SisuC.IdentificationofPotentialBisphenol A
(BPA)ExposureBiomarkersinOvarianCancer.JClinMed.2021May5;10(9):1979. doi:
10.3390/jcm10091979.PMID: 34062972
6.KatopodisP,KerslakeR, DaviesJ, RandevaHS,ChathaK, HallM,SpandidosDA,AnikinV, Polychronis A,
RobertusJL, KyrouI, KarterisE. COVID19 and SARS CoV2 hostcell entrymediators:Expressionprofiling of
TMRSS4inhealthanddisease.IntJMolMed.2021Apr;47(4):64.doi:10.3892/ijmm.2021.4897. Epub
2021 Mar 2.PMID: 33649798
7. Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, GlasspoolRM, Berek JS, de Paiva BatistaM, Hall M, Kim JW,
YeoshouaE, FujiwaraN, NamBH, PolleisS, LeeJY, StrojnaA, FarrellyL, SchwameisR, FossatiR, Darlington
AS, Lai CH, WrightAA, RosenblatO, HarterP, RoxburghP, ChowdhuryRR, ChangTC, PaolettiX, Friedlander
M;GynecologicCancerInterGroup(GCIG)symptombenefitcommittee.Incorporatingpatient centered
benefitsas endpointsin randomizedtrialsof maintenancetherapiesin advancedovariancancer:A position
paperfromtheGCIGsymptombenefitcommittee.GynecolOncol.2021May;161(2):502-507. doi:
10.1016/j.ygyno.2021.02.018. Epub 2021 Feb 19.PMID: 33612336
8. MorganR, McNeishI, CookA, JamesE, LordR, DarkG, GlasspoolR, KrellJ, ParkinsonC, PooleC, Hall M,
Gallardo-RinconD, LockleyM, EssapenS, SummerJ, AnandA, ZachariahgA, WilliamsS, JonesR, Scatchard
K,WaltherA,KimJ-W,SundarS,JaysonG,LedermannJ,ClampA.Objectiveresponsesto first-line
neoadjuvantcarboplatin-paclitaxelregimensforovarian,fallopiantube,orprimaryperitoneal carcinoma
(ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol 2021; 22: 277-88
Page 5
CANCER TREATMENT AND RESEARCH TRUST
for the Year Ended 31 December 2021
Report of the Trustees
STRUCTURE, GOVERNANCE AND MANAGEMENT
9. Muhammed,A.;Fulgenzi,C.A.M*.;Dharmapuri,S.;Pinter,M.;Balcar,L.;Scheiner,B.;Jun,T.;Saeed, A.;
Hildebrand,H.;Navaid,M.;etal.TheSystemicInflammatoryResponseIdentifiesPatientswith Adverse
ClinicalOutcomefromImmunotherapyinHepatocellularCarcinoma.Cancers2021,13, x.
https://doi.org/10.3390/xxxxx. *Co-first author.
10.FulgenziC.A.M.,D'AlessioA.,TalbotT.,GennariA.,OpenshawM.,DemirtasC,CortelliniA.,and Pinato
D.J. New frontiers in the medical therapy of hepatocellular carcinoma. Chemotherapy 2021.
11.BurgioV,IavaroneM,DiCostanzoGG,MarraF,LonardiS,TamburiniE,PiscagliaF,MasiG,Celsa C,
FoschiFG,SillettaM,AmorusoDC,RiminiM,BruccoleriM,TortoraR,CampaniC,SoldàC,Viola MG,
ForgioneA,ContiF,SalaniF,CataneseS,GiacchettoCM,FulgenziC,CoppolaC,LamperticoP,Pellino A,
RancatoreG, CabibboG, RattiF, PedicaF, DellaCorteA, ColomboM, De CobelliF, AldrighettiL, Cascinu S,
CasadeiGardiniA.Real-LifeClinicalDataofLenvatinibversusSorafenibforUnresectable Hepatocellular
Carcinoma in Italy. Cancer Manag Res. 2021;13:9379-9389 https://doi.org/10.2147/CMAR.S330195
12.ParisiA., CortelliniA., VendittiO., FilippiR., SalvatoreL., TortoraG., GhidiniM., NigroO., Gelsomino F.,
ZurloV.I.,FulgenziC.,LombardiP.,RosellóKeränenS.,DepetrisI.,GiampieriR.,MorelliC.,Di MarinoP., Di
PietroF.R.,ZanalettiN.,VitaleP.,GarajovaI.,SpinelliG.P.,ZorattoF.,RobertoM.,PetrilloA.,Aimar G.,
PatrunoL.,D'OrazioC.,FicorellaC.,FerriC.,PorzioG..Post-InductionManagementinPatients With
LeftSidedRASandBRAFWild-TypeMetastaticColorectalCancerTreatedWithFirst-Line Anti-EGFR-Based
Doublet Regimens: A Multicentre Study. Frontiers in Oncology, 2021
13.D'AlessioA.andFulgenziC.A.M.Treatingpatientswithadvancedhepatocellularcarcinoma and
impaired liver function: Broadening the reach of anti-cancer therapy. Liver cancer international, 2021
14.ParisiA.,PorzioG.,CannitaK.,VendittiO.,AvalloneA.,FilippiR.,SalvatoreL.,TortoraG.,Ribelli M.,
NigroO.,GelsominoF.,SpallanzaniA.,ZurloV.,LeoS.,Dell'AquilaE.,FulgenziC.,LombardiP., Roselló
KeränenS., Aimar G., De PetrisI., GiampieriR., MorelliC., De Tursi M., Tinari N., Di PietroF.R., De Galitiis F.,
ZanalettiN.,TroianiT.,VitaleP.,GarajovaI.,GhidiniM.,SpinelliG.P.,ZorattoF.,RobertoM.,Ierino D.,
PetrilloA.,D'OrazioC.,FicorellaC.,CortelliniA. Clinicians'attitudetodoubletplusanti-EGFRversus triplet
plusbevacizumabasfirstlinetreatmentin left-sidedRASandBRAFwild-typemetastaticcolorectal cancer
patients: a multicentre, "real-life", case-control study. Clinical Colorectal Cancer, 2021.
15.RapposelliIG,ShimoseS,KumadaT,OkamuraS,HiraokaA,DiCostanzoGG,MarraF,Tamburini E,
ForgioneA, FoschiFG, SillettaM, LonardiS, Masi G, ScartozziM, NakanoM, ShibataH, KawataK, Pellino A,
VivaldiC,LaiE,TakataA,TajiriK,ToyodaH,TortoraR,CampaniC,ViolaMG,PiscagliaF,ContiF, Fulgenzi
CAM,FrassinetiGL,RizzatoMD,SalaniF,AstaraG,TorimuraT,AtsukawaM,TadaT,BurgioV,Rimini M,
CascinuS, Casadei-GardiniA. Identificationof lenvatinibprognosticindexvia recursivepartitioning analysis
in advanced hepatocellular carcinoma. Esmo open, 2021
16.FulgenziC.A.M.,TalbotT.,MurrayS.M.,SillettaM.,VincenziB.,CortelliniA.andPinato D.J..
Immunotherapy in Hepatocellular Carcinoma. Current Treatment Options in Oncology 2021
17.DemirtasCO*,D'AlessioA*,RimassaL,SharmaR,PinatoDJetal.,2021,ALBIgrade:Evidencefor an
improvedmodelforliverfunctionalestimationinpatientswithhepatocellularcarcinoma,JHEP REPORTS,
Vol: 3 (*shared first authorship)
Page 6
CANCER TREATMENT AND RESEARCH TRUST
for the Year Ended 31 December 2021
Report of the Trustees
STRUCTURE, GOVERNANCE AND MANAGEMENT
18.PinatoDJ,MarronTU,Mishra-KalyaniPS,GongY,WeiG,SzafronD,SharonE,SaeedA,Jun T,
DharmapuriS,NaqashAR,PeeraphatditT,GampaA,WangY,KhanU,MuzaffarM,NavaidM,LeeCJ, Lee
P-C,BulumulleA,YuB,PaulS,NimkarN,BettingerD,HildebrandH,AbugabalY,PressianiT,Personeni N,
D'AlessioA, Kaseb AO, Huang Y-H, Ang C, SchneiderJ, Pillai A, RimassaL, GoldbergKB, Pazdur R, Theoret M,
LemeryS,Fashoyin-AjeL,CortelliniA,PelosofLetal.,2021,Treatment-relatedtoxicityand improved
outcomefromimmunotherapyinhepatocellularcancer:EvidencefromanFDApooledanalysis of
landmarkclinicaltrialswithvalidationfromroutinepractice,EUROPEANJOURNALOFCANCER,Vol: 157,
Pages: 140-152, ISSN: 0959-8049
19.D'AlessioA, RimassaL,CortelliniA, PinatoDJetal.,2021,PD-1BlockadeforHepatocellular Carcinoma:
CurrentResearchandFutureProspects,JOURNALOFHEPATOCELLULARCARCINOMA,Vol:8, Pages:
887-897
20. PinatoDJ, TaberneroJ, BowerM, et al. Prevalenceand impactof COVID-19sequelaeon treatment and
survivalofpatientswithcancerwhorecoveredfromSARS-CoV-2infection:evidencefromthe OnCovid
retrospective,multicentreregistrystudy.TheLancetOncology.Publishedonline 2021.
doi:https://doi.org/10.1016/S1470-2045(21)00573-8
21.PinatoDJ,PatelM,ScottiL,ColombaE,DollyS,LoizidouA,ChesterJ,MukherjeeU,ZambelliA, Dalla
PriaA, Aguilar-CompanyJ, BowerM, SalazarR, BertuzziA, BrunetJ, LambertiniM, TagliamentoM, Pous A,
Sita-LumsdenA, SrikandarajahK, ColombaJ, PommeretF, Seguí E, GeneraliD, GrisantiS, PedrazzoliP, Rizzo
G,LibertiniM,MossC,EvansJS,RussellB,HarbeckN,VincenziB,BielloF,BertulliR,OttavianiD,Liñan R,
RossiS,Carmona-GarcíaMC,TondiniC,FoxL,BaggiA,FotiaV,ParisiA,PorzioG,QueiroloP,Cruz CA,
Saoudi-GonzalezN,FelipE,RoquéLloverasA,Newsom-DavisT,SharkeyR,RoldánE,ReyesR,Zoratto F,
EarnshawI,FerranteD,Marco-HernándezJ,Ruiz-CampsI,GaidanoG,PatriarcaA,BrunaR,Sureda A,
Martinez-VilaC,SanchezdeTorreA,BerardiR,GiustiR,MazzoniF,GuidaA,RimassaL,Chiudinelli L,
FranchiM, KrengliM, SantoroA, PratA, TaberneroJ, VanHemelrijckM, DiamantisN, GennariA, Cortellini
A.Time-DependentCOVID-19MortalityinPatientsWithCancer:AnUpdatedAnalysisofthe OnCovid
Registry. JAMA Oncol. 2021 Nov 24. doi: 10.1001/jamaoncol.2021.6199. Epub ahead of print.
22.GarrigósL,SauraC,Martinez-VilaC,ZambelliA,BowerM,PistilliB,LambertiniM,Ottaviani D,
DiamantisN,LumsdenA,PernasS,GeneraliD,SeguíE,ViñasG,FelipE,SanchezA,RizzoG,Santoro A,
CortelliniA, PeroneY, ChesterJ, IglesiasM, Betti M, VincenziB, LibertiniM, MazzoniF, ZorattoF, Berardi R,
GuidaA,WuerstleinR,LoizidouA,SharkeyR,AguilarCompanyJ,MatasM,SaggiaC,Chiudinelli L,
Colomba-BlamebleE,GalaziM,MukherjeeU,VanHemelrijckM,MarinM,StrinaC,PratA, PlaH, Ciruelos
EM, BertuzziA, Del MastroL, PorzioG, Newsom-DavisT, Ruiz I, DelanyMB, KrengliM, FotiaV, Viansone A,
ChopraN, RomeoM, SalazarR, PerezI, d'AvanzoF, FranchiM, MilaniM, PommeretF, TucciM, Pedrazzoli
P,HarbeckN,FerranteD,PinatoDJ,GennariA.COVID-19inbreastcancerpatients:asubanalysisof the
OnCovidregistry.TherAdvMedOncol.2021Nov2;13:17588359211053416. doi:
10.1177/17588359211053416.
Page 7
CANCER TREATMENT AND RESEARCH TRUST
Report of the Trustees
for the Year Ended 31 December 2021
STRUCTURE, GOVERNANCE AND MANAGEMENT
23.PinatoDJ,ScottiL,GennariA,Colomba-BlamebleE,DollyS,LoizidouA,ChesterJ,Mukherjee U,
ZambelliA, Aguilar-CompanyJ, Bower M, Galazi M, SalazarR, BertuzziA, Brunet J, Mesia R, Sita-Lumsden A,
ColombaJ,PommeretF,SeguíE,BielloF,GeneraliD,GrisantiS,RizzoG,LibertiniM,MossC,Evans JS,
RussellB, WuerstleinR, VincenziB, BertulliR, OttavianiD, Liñan R, MarrariA, Carmona-GarcíaMC, Sng CCT,
TondiniC,MirallasO,TovazziV,FotiaV,CruzCA,Saoudi-GonzalezN,FelipE,RLloverasA,Lee AJX,
Newsom-DavisT,SharkeyR,ChungC,García-IllescasD,ReyesR,SophiaWongYN,Ferrante D,
Marco-HernándezJ,Ruiz-CampsI,GaidanoG,PatriarcaA,SuredaA,Martinez-VilaC,SanchezdeTorre A,
RimassaL, ChiudinelliL, FranchiM, KrengliM, SantoroA, Prat A, TaberneroJ, V HemelrijckM, Diamantis N,
CortelliniA;OnCovidstudygroup.Determinantsofenhancedvulnerabilitytocoronavirusdisease2019 in
UKpatientswithcancer:aEuropeanstudy.EurJCancer.2021Jun;150:190-202. doi:
10.1016/j.ejca.2021.03.035. Epub 2021 Apr 6. PMID: 33932726; PMCID: PMC8023206.
24.SoosaipillaiG,WuA,DettorreGM,DiamantisN,ChesterJ,MossC,Aguilar-CompanyJ,BowerM, Sng
CC,SalazarR,BrunetJ,JonesE,MesiaR,JacksonA,MukherjeeU,Sita-LumsdenA,SeguíE,Ottaviani D,
CarbóA,BenafifS,WürstleinR,CarmonaC,ChopraN,CruzCA,SwallowJ,SaoudiN,FelipE,Galazi M,
Garcia-FructuosoI,LeeAJX,Newsom-DavisT,WongYNS,SuredaA,MaluquerC,Ruiz-CampsI,Cabirta A,
PratA,LoizidouA,GennariA,FerranteD,TaberneroJ,RussellB,VanHemelrijckM,Dolly S,
Hulbert-WilliamsNJ,PinatoDJ.Specialistpalliativeandend-of-lifecareforpatientswithcancer and
SARS-CoV-2infection:aEuropeanperspective.TherAdvMedOncol.2021Sep 2;13:17588359211042224.
doi: 10.1177/17588359211042224. PMID: 34497669; PMCID: PMC8419540.
25.3. DettorreGM,DollyS, LoizidouA, ChesterJ, JacksonA, MukherjeeU, ZambelliA, Aguilar-Company J,
BowerM,SngCCT,SalazarR,BertuzziA,BrunetJ,MesiaR,Sita-LumsdenA,SeguíE,BielloF,Generali D,
GrisantiS,SeevaP,RizzoG,LibertiniM,MaconiA,MossC,RussellB,HarbeckN,VincenziB,Bertulli R,
OttavianiD,LiñanR,MarrariA,Carmona-GarcíaMC,ChopraN,TondiniCA,MirallasO,TovazziV,Fotia V,
CruzCA,Saoudi-GonzalezN,FelipE,RoquéA,LeeAJX,Newsom-DavisT,García-IllescasD,ReyesR, Wong
YNS, FerranteD, ScottiL, Marco-HernándezJ, Ruiz-CampsI, PatriarcaA, RimassaL, ChiudinelliL, Franchi M,
SantoroA, Prat A, GennariA, Van HemelrijckM, TaberneroJ, DiamantisN, PinatoDJ; OnCovidstudy group.
Systemicpro-inflammatoryresponseidentifiespatientswithcancerwithadverseoutcomes from
SARS-CoV-2infection:theOnCovidInflammatoryScore.JImmunotherCancer.2021 Mar;9(3):e002277.
doi:10.1136/jitc-2020-002277.Erratumin: J ImmunotherCancer.2021Jun;9(6):PMID:33753569; PMCID:
PMC7985977.
26.JoffeJK,CaffertyFH,MurphyL,RustinGJS,SohaibSA,GabeR,StenningSP,JamesE,NoorD,Wade S,
SchiavoneF, SwiftS, DunwoodieE, Hall M, SharmaA, BraybrookeJ, ShamashJ, LogueJ, TaylorHH, Hennig
I,WhiteJ,RudmanS,WorldingJ,BloomfieldD,FaustG,GlenH,JonesR,SecklM,MacDonald G,
SreenivasanT,KumarS,ProtheroeA,VenkitaramanR,MazharD,CoyleV,HighleyM,GeldartT,Laing R,
KaplanRS,HuddartRA;TRISSTTrialManagementGroupandInvestigators.ImagingModality and
FrequencyinSurveillanceofStageISeminomaTesticularCancer:ResultsFromaRandomized,Phase III,
Noninferiority Trial (TRISST). J Clin Oncol. 2022 Aug 1;40(22):2468-2478.
27. Maher GJ, Fisher RA, Kaur B, Aguiar X, AravindP, CedenoN, Clark J, DamonD, GhoraniE, Januszewski A,
KalofonouF,MurphyR,RoyR,SarwarN,OpenshawMR,SecklMJ.NPJGenomMed.2022Apr 8;7(1):26.
doi: 10.1038/s41525-022-00297-x.PMID:35396509Sensitivescreeningof single nucleotide polymorphisms
in cell free DNA for diagnosis of gestational tumours.
Page 8
CANCER TREATMENT AND RESEARCH TRUST
for the Year Ended 31 December 2021
Report of the Trustees
STRUCTURE, GOVERNANCE AND MANAGEMENT
28. GeorgiouM, NtavelouP, StokesW, Roy R, Maher GJ, StoilovaT, Choo JAMY, RakhitCP, MartinsM, Ajuh
P,HorowitzN,BerkowitzRS,EliasK,SecklMJ,PardoOE.Oncogene.2022Apr;41(18):2540-2554. doi:
10.1038/s41388-022-02251-8.Epub2022Mar18.ATRandCDK4/6inhibitiontargetthegrowth of
methotrexate-resistant choriocarcinoma.
29.ChrysostomouS,RoyR,PrischiF,ThamlikitkulL,ChapmanKL,MuftiU,PeachR,DingL,Hancock D,
MooreC, Molina-ArcasM, MauriF, PinatoDJ,AbrahamsJM,OttavianiS, CastellanoL, GiamasG, Pascoe J,
MoonamaleD, PirrieS, GauntC, BillinghamL, StevenNM, CullenM, HroudaD, WinklerM, PostJ, Cohen P,
SalpeterSJ,BarV,ZundelevichA,GolanS,LeiboviciD,LaraR,KlugDR,YalirakiSN,BarahonaM,Wang Y,
DownwardJ,SkehelJM,AliMMU,SecklMJ,PardoOE.SciTranslMed.2021Jul14;13(602):eaba4627. doi:
10.1126/scitranslmed.aba4627.PMID:34261798RepurposedfloxacinstargetingRSK4 prevent
chemoresistance and metastasis in lung and bladder cancer.
30.BragaA,PaivaG,GhoraniE,FreitasF,VelardeLGC,KaurB,UnsworthN,Lozano-KuehneJ,Dos Santos
EstevesAPV,RezendeFilhoJ,AmimJJr,AguiarX,SarwarN,EliasKM,HorowitzNS,BerkowitzRS, Seckl
MJ.LancetOncol.2021Aug;22(8):1188-1198.doi:10.1016/S1470-2045(21)00262-X.Epub2021 Jun
25.PMID:34181884Predictorsforsingle-agentresistanceinFIGOscore5or6gestational trophoblastic
neoplasia: a multicentre, retrospective, cohort study.
31. Cortés-CharryR, Hennah L, FroelingFEM, Short D, Aguiar X, Tin T, HarveyR, UnsworthN, Kaur B, Savage
P, SarwarN, SecklMJ.ESMOOpen.2021Jun;6(3):100110.doi:10.1016/j.esmoop.2021.100110.Epub 2021
Apr10.PMID:33845362Increasingthehumanchorionicgonadotrophincut-offto?1000IU/lfor starting
actinomycinDinpost-molargestationaltrophoblasticneoplasiadevelopingresistanceto methotrexate
spares more women multi-agent chemotherapy.
32.PaulNathan,JessicaC.Hassel,PiotrRutkowski,Jean-FrancoisBaurain,MarcusO.Butler,Max Schlaak,
RyanJ.Sullivan,SebastianOchsenreither,ReinhardDummer,JohnM.Kirkwood,AnthonyM. Joshua,
JosephJ.Sacco,AlexanderN.Shoushtari,MarlanaOrloff,JosepM.Piulats,MohammedMilhem,April K.S.
Salama,BrendanCurti,Lev Demidov,LaurisGastaud,CorneliaMauch,MelindaYushak,RichardD. Carvajal,
OmidHamid,ShaadE.Abdullah,ChrisHolland,HowardGoodall,andSophiePiperno-Neumann,for the
IMCgp100-202 Investigators.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
N Engl J Med. 2021 Sep 23;385(13):1196-1206
33. AlexanderJL, IbraheimH, Sheth B, LittleJ, Khan MS, RichardsC, Hunter N, ChauhanD, Ratnakumaran R,
McHughK, PinatoDJ, NathanP, ChoyJ, CruszSM, FurnessA, TurajlicS, PickeringL, LarkinJ, TeareJP, Papa
S,SpeightA,SharmaA,PowellN.Clinicaloutcomesofpatientswithcorticosteroidrefractory immune
checkpoint inhibitor-induced enterocolitis treated with infliximab.
J Immunother Cancer. 2021 Jul;9(7)
34. Brase JC, WalterRFH, SavchenkoA, GusenleitnerD, GarrettJ, SchimmingT, VaraljaiR, CastellettiD, Kim
J, DakappagariN, SchultzK, RobertC, LongGV,NathanPD,RibasA, FlahertyKT,KaraszewskaB, Schachter
J,SuckerA,SchmidKW,ZimmerL,LivingstoneE,GasalE,SchadendorfD,RoeschA.Role of
Tumor-InfiltratingBCellsinClinicalOutcomeofPatientswithMelanomaTreatedWithDabrafenib Plus
Trametinib.
Clin Cancer Res. 2021 Aug 15;27(16):4500-4510. doi: 10.1158/1078-0432.CCR-20-3586. Epub 2021 Jun 9
Page 9
CANCER TREATMENT AND RESEARCH TRUST
Report of the Trustees
for the Year Ended 31 December 2021
STRUCTURE, GOVERNANCE AND MANAGEMENT
35. Syeda MM, WigginsJM, CorlessBC, Long GV, FlahertyKT, SchadendorfD, NathanPD, RobertC, Ribas A,
DaviesMA, Grob JJ, GasalE, SquiresM, MarkerM, GarrettJ, BraseJC, PolskyD.CirculatingtumourDNA in
patientswithadvancedmelanomatreatedwithdabrafenibordabrafenibplustrametinib:a clinical
validation study.
Lancet Oncol. 2021 Mar;22(3):370-380. doi: 10.1016/S1470-2045(20)30726-9. Epub 2021 Feb 12.
36.EmmaLidington,AmyDin,SusanahStanway,AnandSharma,OlgaHusson.Describingthe supportive
careneedsamongyoungadultswithcancer(25-39years)andtherelationshipwithhealth-related quality
oflife,psychologicaldistressandillnesscognitions.JournalofClinicalMedicine,J.Clin.Med.2021, 10,
4449
37.Clinicaloutcomesofpatientswithcorticosteroidrefractoryimmunecheckpoint inhibitor-induced
enterocolitistreatedwithinfliximab.AlexanderJL,SharmaA,PowellN.JImmunotherCancer. 2021
Jul;9(7):e002742. doi: 10.1136/jitc-2021-002742. PMID: 34233964; PMCID: PMC8264884
38. Biomarkersin bladdercancersurveillance-SukumarSugeeta,SharmaAnand,KenrickNg, Nikhil Vasdev.
Frontiers in Surgery, Sept 2021; Volume 8;735868.
39.UrinaryBiomarkersinBladderCancer:AReviewofTheCurrentLandscapeandFuture Directions.
Anand Sharma, Nikhil Vasdev. Urologic Oncology. Urol Oncol. 2021 Jan;39(1):41-51
40. TreatmentOutcomesfor SmallCell Carcinomaof the Bladder:ResultsFroma UK Patient Retrospective
Cohort Study. Chau C, Sharma A, Crabb S. Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1143-1150.
TheTrusteesareconfidentthattheCTRTwillcontinuetofundtheworkthatwillleadtoimprovements in
the detection, monitoring and treatment of cancer and care for patients with cancer.
REFERENCE AND ADMINISTRATIVE DETAILS Registered Charity number
292909
Principal address
The Clocktower
Mount Vernon Cancer Centre
Rickmansworth Road
Northwood
Middlesex
HA6 2RN
Page 10
CANCER TREATMENT AND RESEARCH TRUST
Report of the Trustees
for the Year Ended 31 December 2021
Trustees
Professor G Rustin
R Ellison
Dr. P Nathan
Professor M Hall Chair of Trustees
Professor M J Seckl
Dr A Sharma
Dr A Polychronis
Dr D J Pinato
R J Hallam
Independent Examiner
Mr Ryan Cottington, ACA, FCCA
Sandison Lang Limited
2 St Marys Road
Tonbridge
Kent
TN9 2LB
Approved by order of the board of trustees on 29 June 2023 and signed on its behalf by:
Professor M Hall - Trustee
Page 11
Independent Examiner's Report to the Trustees of
Cancer Treatment And Research Trust
Independent examiner's report to the trustees of Cancer Treatment And Research Trust
I reportto the charitytrusteeson my examinationof the accountsof CancerTreatmentAnd Research Trust
(the Trust) for the year ended 31 December 2021.
Responsibilities and basis of report
AsthecharitytrusteesoftheTrustyouareresponsibleforthepreparationoftheaccountsin accordance
with the requirements of the Charities Act 2011 ('the Act').
I reportin respectof myexaminationof theTrust'saccountscarriedoutunderSection145of theAct and
incarryingoutmyexaminationIhavefollowedallapplicableDirectionsgivenbytheCharity Commission
under Section 145(5)(b) of the Act.
Independent examiner's statement
Ihavecompletedmyexamination.Iconfirmthatnomaterialmattershavecometomyattention in
connection with the examination giving me cause to believe that in any material respect:
1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.
Ihavenoconcernsandhavecomeacrossnoothermattersinconnectionwiththeexaminationto which
attentionshouldbedrawninthisreportinordertoenableaproperunderstandingoftheaccountsto be
reached.
Mr Ryan Cottington, ACA, FCCA
Sandison Lang Limited
2 St Marys Road
Tonbridge
Kent
TN9 2LB
29 June 2023
Page 12
CANCER TREATMENT AND RESEARCH TRUST
Statement of Financial Activities
for the Year Ended 31 December 2021
Notes
INCOME AND ENDOWMENTS FROM
Donations and legacies
Other trading activities
2
Investment income
3
Other income
Total
EXPENDITURE ON
Raising funds
Charitable activities
Office expenses
Total
NET INCOME/(EXPENDITURE)
RECONCILIATION OF FUNDS
Total funds brought forward
TOTAL FUNDS CARRIED FORWARD |
Unrestricted
fund
£
904
-
117
-
1,021
19,060
124,909
143,969
(142,948)
842,979
700,031 |
Restricted
fund
£
137,450
41,341
-
14,700
193,491
-
477
477
193,014
156,397
349,411 |
2021
Total
funds
£
138,354
41,341
117
14,700
194,512
19,060
125,386
144,446
50,066
999,376
1,049,442 |
2020
Total
funds
£
227,995
-
102
- |
|
|
|
|
228,097 |
|
|
|
|
19,833
190,998 |
|
|
|
|
210,831 |
|
|
|
|
17,266
982,110 |
|
|
|
|
999,376 |
The notes form part of these financial statements
Page 13
CANCER TREATMENT AND RESEARCH TRUST
Balance Sheet
31 December 2021
Notes
FIXED ASSETS
Tangible assets
7
Investments
8
CURRENT ASSETS
Debtors
9
Cash at bank
CREDITORS
Amounts falling due within one year
10
NET CURRENT ASSETS
TOTAL ASSETS LESS CURRENT LIABILITIES
NET ASSETS
FUNDS
11
Unrestricted funds
Restricted funds
TOTAL FUNDS |
Unrestricted
fund
£
492
6,469
6,961
933
713,642
714,575
(21,505)
693,070
700,031
700,031 |
Restricted
fund
£
685
-
685
28,398
322,483
350,881
(2,155)
348,726
349,411
349,411 |
2021
Total
funds
£
1,177
6,469
7,646
29,331
1,036,125
1,065,456
(23,660)
1,041,796
1,049,442
1,049,442
700,031
349,411
1,049,442 |
2020
Total
funds
£
1,370
6,469
7,839
44,374
962,874
1,007,248
(15,711)
991,537
999,376
999,376
842,979
156,397
999,376 |
|
|
|
|
|
The financialstatementswere approvedby the Boardof Trusteesand authorisedfor issue on 29 June 2023
and were signed on its behalf by:
M Hall - Trustee
The notes form part of these financial statements
Page 14
CANCER TREATMENT AND RESEARCH TRUST
Notes to the Financial Statements
for the Year Ended 31 December 2021
1. ACCOUNTING POLICIES
Basis of preparing the financial statements
Thefinancialstatementsofthecharity,whichisapublicbenefitentityunderFRS102,have been
preparedinaccordancewiththeCharitiesSORP(FRS102)'AccountingandReportingby Charities:
StatementofRecommendedPracticeapplicabletocharitiespreparingtheiraccountsin accordance
withtheFinancialReportingStandardapplicableintheUKandRepublicofIreland(FRS 102)
(effective1January2019)',FinancialReportingStandard102'TheFinancialReporting Standard
applicableintheUKandRepublicofIreland'andtheCharitiesAct2011.Thefinancial statements
havebeenpreparedunderthehistoricalcostconvention,withtheexceptionofinvestments which
are included at market value.
Financial reporting standard 102 - reduced disclosure exemptions
Thecharityhastakenadvantageofthefollowingdisclosureexemptionsin preparingthese financial
statements,aspermittedbyFRS102'TheFinancialReportingStandardapplicableintheUK and
Republic of Ireland':
the requirements of Section 7 Statement of Cash Flows.
Income
Allincomeis recognisedin theStatementofFinancialActivitiesoncethecharityhasentitlement to
the funds, it is probable that the income will be received and the amount can be measured reliably.
Expenditure
Liabilitiesarerecognisedasexpenditureassoonasthereisalegalorconstructive obligation
committingthe charityto that expenditure,it is probablethat a transferof economicbenefitswill be
requiredinsettlementandtheamountoftheobligationcanbemeasuredreliably.Expenditure is
accountedforonanaccrualsbasisandhasbeenclassifiedunderheadingsthataggregateall cost
relatedtothecategory.Wherecostscannotbedirectlyattributedtoparticularheadingsthey have
been allocated to activities on a basis consistent with the use of resources.
Grantsofferedsubjecttoconditionswhichhavenotbeenmetattheyearenddatearenotedas a
commitment but not accrued as expenditure.
Tangible fixed assets
Depreciationisprovidedatthefollowingannualratesinordertowriteoffeachassetover its
estimated useful life.
Computer equipment- 25% on reducing balance
Taxation
The charity is exempt from tax on its charitable activities.
Fund accounting
Unrestrictedfundscanbe usedin accordancewiththecharitableobjectivesat thediscretionof the
trustees.
continued...
Page 15
CANCER TREATMENT AND RESEARCH TRUST
Notes to the Financial Statements - continued
for the Year Ended 31 December 2021
1. ACCOUNTING POLICIES - continued
Fund accounting
Restrictedfunds can only be used for particularrestrictedpurposeswithin the objectsof the charity.
Restrictionsarisewhenspecifiedbythedonororwhenfundsareraisedforparticular restricted
purposes.
Furtherexplanationofthenatureandpurposeofeachfundis includedin thenotestothe financial
statements.
Pension costs and other post-retirement benefits
The charityoperatesa definedcontributionpensionscheme.Contributionspayableto the charity's
pensionschemearechargedtotheStatementofFinancialActivitiesintheperiodtowhich they
relate.
2. OTHER TRADING ACTIVITIES
2.
OTHER TRADING ACTIVITIES |
|
|
|
Recharged expenses
3.
INVESTMENT INCOME
Deposit account interest
Dividends |
2021
£
41,341
2021
£
9
108
117 |
|
2020
£
- |
|
|
|
2020
£
102
- |
|
|
|
102 |
4. TRUSTEES' REMUNERATION AND BENEFITS
Therewerenotrustees'remunerationorotherbenefitsfortheyearended31December2021 nor
for the year ended 31 December 2020.
continued...
Page 16
CANCER TREATMENT AND RESEARCH TRUST
Notes to the Financial Statements - continued
for the Year Ended 31 December 2021
4. TRUSTEES' REMUNERATION AND BENEFITS - continued
Trustees' expenses
There were no Trusteeexpensespaid in the year ended 31st December2021.(£139for 1 trustee for
31st December 2020).
5. STAFF COSTS
The average monthly number of employees during the year was as follows:
Secretary/Administration
No employees received emoluments in excess of £60,000.
COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES
Unrestricted
fund
£
INCOME AND ENDOWMENTS FROM
Donations and legacies
101,884
Investment income
102
Total
101,986
EXPENDITURE ON
Raising funds
19,833
Charitable activities
Office expenses
75,161
Total
94,994
NET INCOME
6,992
RECONCILIATION OF FUNDS
Total funds brought forward
835,987
TOTAL FUNDS CARRIED FORWARD
842,979 |
2021
1
Restricted
fund
£
126,111
-
126,111
-
115,837
115,837
10,274
146,123
156,397 |
2020
1
Total
funds
£
227,995
102 |
|
|
228,097 |
|
|
19,833
190,998 |
|
|
210,831 |
|
|
17,266
982,110 |
|
|
999,376 |
6. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES
continued...
Page 17
CANCER TREATMENT AND RESEARCH TRUST
Notes to the Financial Statements - continued for the Year Ended 31 December 2021
7. TANGIBLE FIXED ASSETS
7. |
TANGIBLE FIXED ASSETS |
|
|
|
Computer |
|
|
equipment |
|
|
£ |
|
COST |
|
|
At 1 January 2021 |
3,888 |
|
Additions |
199 |
|
At 31 December 2021 |
4,087 |
|
DEPRECIATION |
|
|
At 1 January 2021 |
2,518 |
|
Charge for year |
392 |
|
At 31 December 2021 |
2,910 |
|
NET BOOK VALUE |
|
|
At 31 December 2021 |
1,177 |
|
At 31 December 2020 |
1,370 |
8. |
FIXED ASSET INVESTMENTS |
|
|
|
Listed |
|
|
investments |
|
|
£ |
|
MARKET VALUE |
|
|
At 1 January 2021 and |
|
|
31 December 2021 |
6,469 |
|
NET BOOK VALUE |
|
|
At 31 December 2021 |
6,469 |
|
At 31 December 2020 |
6,469 |
There were no investment assets outside the UK.
continued...
Page 18
CANCER TREATMENT AND RESEARCH TRUST
Notes to the Financial Statements - continued
for the Year Ended 31 December 2021
9.
DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade debtors
Prepayments and accrued income
Accruals
10.
CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Taxation and social security
Other creditors
11.
MOVEMENT IN FUNDS
Unrestricted funds
General fund
Restricted funds
Restricted Fund
TOTAL FUNDS |
At 1/1/21
£
842,979
156,397
999,376 |
2021
2020
£
£
13,420
-
14,978
44,374
933
-
29,331
44,374
2021
2020
£
£
277
-
23,383
15,711
23,660
15,711
Net
movement
At
in funds
31/12/21
£
£
(142,948)
700,031
193,014
349,411
50,066
1,049,442 |
2020
£
-
44,374
-
44,374
2020
£
-
15,711
15,711
At
31/12/21
£
700,031
349,411 |
2020
£
-
44,374
- |
|
|
|
|
44,374 |
|
|
|
|
2020
£
-
15,711 |
|
|
|
|
15,711 |
continued...
Page 19
CANCER TREATMENT AND RESEARCH TRUST
Notes to the Financial Statements - continued for the Year Ended 31 December 2021
11. MOVEMENT IN FUNDS - continued
Net movement in funds, included in the above are as follows:
Unrestricted funds
General fund
Restricted funds
Restricted Fund
TOTAL FUNDS
Comparatives for movement in funds
Unrestricted funds
General fund
Restricted funds
Restricted Fund
TOTAL FUNDS |
Incoming
resources
£
1,021
193,491
194,512
At 1/1/20
£
835,987
146,123
982,110 |
Resources
Movement
expended
in funds
£
£
(143,969)
(142,948)
(477)
193,014
(144,446)
50,066
Net
movement
At
in funds
31/12/20
£
£
6,992
842,979
10,274
156,397
17,266
999,376 |
|
|
|
continued...
Page 20
CANCER TREATMENT AND RESEARCH TRUST
Notes to the Financial Statements - continued
for the Year Ended 31 December 2021
11. MOVEMENT IN FUNDS - continued
Comparative net movement in funds, included in the above are as follows:
|
Incoming |
Resources |
Movement |
|
resources |
expended |
in funds |
|
£ |
£ |
£ |
Unrestricted funds |
|
|
|
General fund |
101,986 |
(94,994) |
6,992 |
Restricted funds |
|
|
|
Restricted Fund |
126,111 |
(115,837) |
10,274 |
TOTAL FUNDS |
228,097 |
(210,831) |
17,266 |
A current year 12 months and prior year 12 months combined position is as follows: |
|
|
|
|
|
Net |
|
|
|
movement |
At |
|
At 1/1/20 |
in funds |
31/12/21 |
|
£ |
£ |
£ |
Unrestricted funds |
|
|
|
General fund |
835,987 |
(135,956) |
700,031 |
Restricted funds |
|
|
|
Restricted Fund |
146,123 |
203,288 |
349,411 |
TOTAL FUNDS |
982,110 |
67,332 |
1,049,442 |
continued...
Page 21
CANCER TREATMENT AND RESEARCH TRUST
Notes to the Financial Statements - continued
for the Year Ended 31 December 2021
11. MOVEMENT IN FUNDS - continued
Acurrentyear12monthsandprioryear12monthscombinednetmovementinfunds,included in
the above are as follows:
Unrestricted funds
General fund
Restricted funds
Restricted Fund
TOTAL FUNDS |
Incoming
resources
£
103,007
319,602
422,609 |
Resources
Movement
expended
in funds
£
£
(238,963)
(135,956)
(116,314)
203,288
(355,277)
67,332 |
|
|
|
12. RELATED PARTY DISCLOSURES
There were no related party transactions for the year ended 31 December 2021.
Page 22
CANCER TREATMENT AND RESEARCH TRUST
Detailed Statement of Financial Activities
for the Year Ended 31 December 2021
INCOME AND ENDOWMENTS
Donations and legacies
Donations
Other trading activities
Recharged expenses
Investment income
Deposit account interest
Dividends
Other income
Sundry income
Total incoming resources
EXPENDITURE
Raising donations and legacies
Administrator
Events expenses
Charitable activities
Pensions
Research salaries
Research expenses and lab fees
Research conferences/meetings
Subscriptions
Postage and stationery
Computer expenses
Sundries
Depreciation of tangible fixed assets
Carried forward |
2021
£
138,354
41,341
9
108
117
14,700
194,512
14,000
5,060
19,060
214
59,266
49,931
335
1,191
423
240
-
389
111,989 |
2020
£
227,995
-
102
- |
|
|
102
- |
|
|
228,097
19,233
600 |
|
|
19,833
-
97,012
79,895
2,428
-
183
217
2,687
481
182,903 |
This page does not form part of the statutory financial statements
Page 23
CANCER TREATMENT AND RESEARCH TRUST
Detailed Statement of Financial Activities
for the Year Ended 31 December 2021
Charitable activities
Brought forward
Grants to institutions
Support costs
Management
Insurance
Telephone
Advertising
Sundries
Finance
Bank charges
Governance costs
Accountancy
Professional fees
Total resources expended
Net income |
2021
£
111,989
5,000
116,989
47
34
38
209
328
782
6,878
409
7,287
144,446
50,066 |
2020
£
182,903
- |
|
|
182,903
200
477
-
- |
|
|
677
70
4,805
2,543 |
|
|
7,348 |
|
|
210,831 |
|
|
17,266 |
This page does not form part of the statutory financial statements
Page 24